{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:40:40Z","timestamp":1785760840194,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2015\/387"],"award-info":[{"award-number":["CAN 2015\/387"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2018\/362"],"award-info":[{"award-number":["CAN 2018\/362"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-05973"],"award-info":[{"award-number":["2018-05973"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.compbiomed.2023.107826","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T01:04:54Z","timestamp":1701911094000},"page":"107826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models"],"prefix":"10.1016","volume":"169","author":[{"given":"H. Jonathan G.","family":"Lindstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid S.","family":"de Wijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":false,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.compbiomed.2023.107826_b1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol.\/Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107826_b2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","article-title":"Recent developments in drug resistance mechanism in chronic myeloid leukemia: A review","volume":"87","author":"Vaidya","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107826_b3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR\u2013ABL TKIs and the therapeutic strategies: A review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107826_b4","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.18632\/oncotarget.7459","article-title":"Drug resistance in cancer: Molecular evolution and compensatory proliferation","volume":"7","author":"Friedman","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107826_b5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic Myeloid Leukaemia","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.compbiomed.2023.107826_b6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","article-title":"Evolution of acquired resistance to anti-cancer therapy","volume":"355","author":"Foo","year":"2014","journal-title":"J. Theoret. Biol."},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107826_b7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrc4029","article-title":"The mathematics of cancer: Integrating quantitative models","volume":"15","author":"Altrock","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.compbiomed.2023.107826_b8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic Myeloid Leukemia: Functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107826_b9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic Myeloid Leukemia","volume":"4","author":"Komarova","year":"2009","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107826_b10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027682","article-title":"Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia","volume":"6","author":"Leder","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107826_b11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12885-019-5690-5","article-title":"Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia","volume":"19","author":"Lindstr\u00f6m","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107826_b12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11538-010-9539-y","article-title":"The worst drug rule revisited: Mathematical modeling of Cyclic cancer treatments","volume":"73","author":"Katouli","year":"2010","journal-title":"Bull. Math. Biol."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107826_b13","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1021\/mp200270v","article-title":"Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"8","author":"Mumenthaler","year":"2011","journal-title":"Mol. Pharmaceut."},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107826_b14","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1039\/C5MB00110B","article-title":"S100A4 and its role in metastasis \u2013 computational integration of data on biological networks","volume":"11","author":"Buetti-Dinh","year":"2015","journal-title":"Mol. BioSyst."},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107826_b15","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1039\/C5MB00302D","article-title":"S100A4 and its role in metastasis \u2013 simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases","volume":"11","author":"Buetti-Dinh","year":"2015","journal-title":"Mol. BioSyst."},{"issue":"9","key":"10.1016\/j.compbiomed.2023.107826_b16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163011","article-title":"Sensitivity analysis of the NPM-ALK signalling network reveals important pathways for anaplastic large cell lymphoma combination therapy","volume":"11","author":"Buetti-Dinh","year":"2016","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.compbiomed.2023.107826_b17","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/0008-5472.CAN-16-2871","article-title":"Pharmacokinetics and drug interactions determine optimum combination strategies in computational models of cancer evolution","volume":"77","author":"Chakrabarti","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107826_b18","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-018-2145-y","article-title":"Computer simulations of the signalling network in FLT3+-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6","volume":"19","author":"Buetti-Dinh","year":"2018","journal-title":"BMC Bioinform."},{"issue":"7046","key":"10.1016\/j.compbiomed.2023.107826_b19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107826_b20","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.77.021915","article-title":"Multiple mutant clones in blood rarely coexist","volume":"77","author":"Dingli","year":"2008","journal-title":"Phys. Rev. E"},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107826_b21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLK.2008.n.017","article-title":"Chronic Myeloid Leukemia: Origin, development, response to therapy, and relapse","volume":"2","author":"Dingli","year":"2008","journal-title":"Clin. Leukemia"},{"issue":"19","key":"10.1016\/j.compbiomed.2023.107826_b22","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic Myeloid Leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107826_b23","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: Investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leukemia Lymphoma"},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107826_b24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161470","article-title":"ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines","volume":"11","author":"Eadie","year":"2016","journal-title":"PLoS One"},{"issue":"78","key":"10.1016\/j.compbiomed.2023.107826_b25","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26187","article-title":"Modelling ponatinib resistance in tyrosine kinase inhibitor-na&#xEF;ve and dasatinib resistant BCR-ABL1+ cell lines","volume":"9","author":"Lu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.compbiomed.2023.107826_b26","series-title":"Methods in Molecular Biology","first-page":"77","article-title":"Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells","author":"Calcagno","year":"2009"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107826_b27","doi-asserted-by":"crossref","DOI":"10.18388\/abp.2016_1396","article-title":"Reactive oxygen species in BCR-ABL1-expressing cells \u2013 relevance to chronic myeloid leukemia","volume":"64","author":"Antoszewska-Smith","year":"2016","journal-title":"Acta Biochim. Pol."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107826_b28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.lungcan.2011.11.007","article-title":"Conversion from the \u201concogene addiction\u201d to \u201cdrug addiction\u201d by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation","volume":"76","author":"Suda","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107826_b29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","article-title":"Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma","volume":"8","author":"Hong","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.compbiomed.2023.107826_b30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exphem.2020.11.006","article-title":"Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response","volume":"94","author":"Roeder","year":"2021","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.compbiomed.2023.107826_b31","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-23-0398","article-title":"Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles","author":"Miroshnychenko","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.compbiomed.2023.107826_b32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2020.110162","article-title":"Understanding the role of phenotypic switching in cancer drug resistance","volume":"490","author":"Gunnarsson","year":"2020","journal-title":"J. Theoret. Biol."},{"issue":"51","key":"10.1016\/j.compbiomed.2023.107826_b33","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"16","key":"10.1016\/j.compbiomed.2023.107826_b34","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to Imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"MCB"},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107826_b35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","article-title":"The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia","volume":"1863","author":"Georgoulia","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA) - Gen. Subj."},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107826_b36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102238","article-title":"Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib","volume":"298","author":"Oruganti","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.compbiomed.2023.107826_b37","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/j100540a008","article-title":"Exact stochastic simulation of coupled chemical reactions","volume":"81","author":"Gillespie","year":"1977","journal-title":"J. Phys. Chem."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107826_b38","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1214\/105051605000000098","article-title":"The branching process with logistic growth","volume":"15","author":"Lambert","year":"2005","journal-title":"Ann. Appl. Probab."},{"issue":"20","key":"10.1016\/j.compbiomed.2023.107826_b39","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1093\/bioinformatics\/bty361","article-title":"pyABC: Distributed, likelihood-free inference","volume":"34","author":"Klinger","year":"2018","journal-title":"Bioinformatics"},{"issue":"90","key":"10.1016\/j.compbiomed.2023.107826_b40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non\u2013small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107826_b41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-09048-5","article-title":"Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model","volume":"12","author":"Lindstr\u00f6m","year":"2022","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107826_b42","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1016\/j.celrep.2020.02.108","article-title":"Multi-scale predictions of drug resistance epidemiology identify design principles for rational drug design","volume":"30","author":"Leighow","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107826_b43","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01856-5","article-title":"Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.compbiomed.2023.107826_b44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","article-title":"Treatment of evolving cancers will require dynamic decision support","volume":"34","author":"Strobl","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107826_b45","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-018-0532-2","article-title":"When to stop tyrosine kinase inhibitors for the treatment of chronic Myeloid Leukemia","volume":"19","author":"Laneuville","year":"2018","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"17","key":"10.1016\/j.compbiomed.2023.107826_b46","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","article-title":"Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis","volume":"26","author":"Eyler","year":"2008","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107826_b47","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001048252301291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001048252301291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:58:03Z","timestamp":1720573083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001048252301291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":47,"alternative-id":["S001048252301291X"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107826","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107826"}}